Darmstadt, Germany, July 28, 2010 - Merck KGaA announced today
that the U.S. Food and Drug Administration (FDA) has accepted for
filing the New Drug Application (NDA) for Cladribine Tablets as a
therapy for relapsing forms of multiple sclerosis... (Source: Drugs.com - New Drug Applications)
Posted: 2010-07-28 08:07:09
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
Pediatric Multiple Sclerosis
FAQ's > Types of MS
Multiple Sclerosis Types
FAQ's > Types of MS
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
